Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

Table 6 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy alone (early vs no recurrence)

	Early vs no recurrence in endocrine therapy group
	Univariate analysis	p Value	Multivariate analysis	p Value
ALDH1, ≤1 %/>1 %	1.804 (0.651–4.609)	0.244	Not selected
Age, ≤50/>50 years	0.996 (0.526–1.932)	0.992	Not selected
Tumor size, ≤20/>20 mm	6.182 (3.208–12.383)	<0.001	4.910 (2.469–10.076)	<0.001
Nodal metastasis negative/positive	3.344 (1.543–7.181)	0.002	2.894 (1.229–6.777)	0.002
Progesterone receptor staining, <20 %/≥20 %	0.708 (0.382–1.313)	0.272	Not selected
Ki-67 staining, <20 %/≥20 %	1.441 (0.619–3.159)	0.383	Not selected
Tumor grade 1 or 2/3	2.615 (1.666–4.128)	<0.001	2.820 (1.296–6.111)	<0.001

ISSN: 1465-542X